Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control

 
• By Sten Stovall

California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.

ScienceLab
Tizona and AbbVie hope to develop and commercialize CD39-targeted therapeutics • Source: Shutterstock

More from Business

More from Scrip